How effective is Ampyra for Relapsing-remitting Multiple Sclerosis? (a real world drug study)
Summary:
Overall ratings: 3.8/5 Long term ratings: 3.5/5
This is a phase IV clinical study of how effective Ampyra (dalfampridine) is for Relapsing-remitting multiple sclerosis and for what kind of people. The study is created by eHealthMe from 8 Ampyra users and is updated continuously.
What is Ampyra?
Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 77,145 Ampyra users. Check the latest studies of Ampyra.
What is Relapsing-remitting multiple sclerosis?
Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 126 drugs and 178 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.
8 people are studied for taking Ampyra in Relapsing-remitting multiple sclerosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Ampyra effectiveness for Relapsing-remitting multiple sclerosis (number of people):
Overall:
- not at all: 0
- somewhat: 0
- moderate: 3
- high: 4
- very high: 1
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 3
- high: 3
- very high: 0
Gender of people who take Ampyra for Relapsing-remitting multiple sclerosis *:
- female: 87.5 %
- male: 12.5 %
Age of people who take Ampyra for Relapsing-remitting multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 12.5 %
- 40-49: 62.5 %
- 50-59: 12.5 %
- 60+: 12.5 %
Who find Ampyra more effective for Relapsing-remitting Multiple Sclerosis?
Gender of people who take Ampyra for Relapsing-remitting multiple sclerosis *:
- female: 80 %
- male: 20 %
Age of people who take Ampyra for Relapsing-remitting multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 20 %
- 40-49: 40 %
- 50-59: 20 %
- 60+: 20 %
* Approximation only. Some reports may have incomplete information.
Do you take Ampyra?
- You can start a phase IV clinical trial to monitor Ampyra safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related studies
Alternative drugs to, pros and cons of:
- Ampyra (77,145 reports)
Treatments, associated drugs and conditions:
- Relapsing-remitting multiple sclerosis (76,275 reports)
How the study uses the data?
The study is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Vitamin D and Labetalol Hydrochloride - now
- Drug interactions of Silybum Marianum and Lopurin - 5 seconds ago
- Drug interactions of Revlimid and Busulfex - 21 seconds ago
- Could Nucala cause Hyperthyroidism? - 32 seconds ago
- Could Zantac cause Gallbladder Disease? - 47 seconds ago
- Could Avonex cause Jaundice Neonatal? - 57 seconds ago
- Drug interactions of Jakafi and Lotensin - a minute ago
- Could Celexa cause Bundle Branch Block Right? - a minute ago
- Could Zicam cause Fear? - a minute ago
- Could Calcium cause Micturition Frequency Decreased? - a minute ago